To include your compound in the COVID-19 Resource Center, submit it here.

FDA may block generic Opana sales

FDA is considering taking regulatory action to prevent the marketing of products containing oxymorphone, such as Opana ER oxymorphone extended release from Endo International plc (NASDAQ:ENDP), FDA Commissioner Scott Gottlieb announced Friday.

In

Read the full 337 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE